MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Exclusion Criteria

• •Transformed lymphoma.
• •Primary central nervous system lymphoma, primary effusion lymphoma, primary mediastinal DLBCL, DLBCL of the testis, primary cutaneous DLBCL or histologic evidence of transformation to a Burkitt lymphoma.
• •History of other cancer, including one that has been treated but not with curative intent, unless the cancer has been in remission without treatment for \>/= 5 years prior to dosing. Note: Participants with a history of cured skin cancer or in situ carcinoma of the cervix are eligible for the study.
• •Ongoing corticosteroid use \> 30 mg/day of prednisone or equivalent. Note: Participants receiving corticosteroid treatment with \</= 30 mg/day of prednisone or equivalent must be on a stable regimen for at least 4 weeks prior to start of dosing.
• •Inadequate renal, hematologic, or hepatic function.
• •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.
• •For participants with DLBCL: Contraindication to any of the individual components of CHOP (cyclophosphamide, vincristine, doxorubicin and prednisone), including prior anthracycline treatment.
• •For participants with FL: contraindication to standard chemotherapy.
• •Other serious underlying medical conditions.
• •Recent major surgery (within 4 weeks prior to dosing), other than for diagnosis.
• •Active and/or severe infections (excluding nail fungal infections) or any infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to dosing.
• •Active Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection. Note: Participants testing positive for Hepatitis B or C virus antibodies but with an undetectable viral load may be included.
• •History of Human Immunodeficiency Virus (HIV) positive status.